Rein Therapeutics Inc. (RNTX) delivered a return of -31.29% over the past year. Since RNTX does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Rein Therapeutics Inc. one year ago would be worth $6,871 today, representing a loss of $3,129.

Rein Therapeutics Inc. (RNTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For RNTX, the total return equals the price-only return.

No, Rein Therapeutics Inc. (RNTX) underperformed the S&P 500 by 52.13 percentage points over the past year. RNTX delivered a total return of -31.29%, compared to the S&P 500's 20.84%. This means a passive S&P 500 index fund outperformed RNTX by 52.13pp during this period.

Rein Therapeutics Inc. (RNTX) experienced a maximum drawdown of -53.99% over the past year, declining from its peak on 2026-04-22 to its trough on 2026-06-17. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Rein Therapeutics Inc. (RNTX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -52.4% (-7.1% CAGR) — $10,000 would have grown to $4,764. Over 20 years: -52.4% total return (-3.6% CAGR) — $10,000 → $4,764. Over 30 years: -52.4% total return (-2.4% CAGR) — $10,000 → $4,764. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Rein Therapeutics Inc.'s best calendar year was 2024 with a total return of 8.5%. Its worst year was 2025 with a total return of -48.4%. This range shows the volatility investors should expect — the difference between the best and worst year is 56.9 percentage points.